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Persisting high prevalence of pneumococcal carriage
among HIV-infected adults receiving antiretroviral
therapy in Malawi: a cohort study
Ellen Heinsbroeka, Terence Tafatathab, Amos Phirib, Bagrey Ngwirab,c,
Amelia C. Crampinb,d, Jonathan M. Reade and Neil Frencha
Objective: HIV-infected adults have high rates of pneumococcal carriage and invasive
disease. We investigated the effect of antiretroviral therapy (ART) on pneumococcal
carriage in HIV-infected adults prior to infant pneumococcal conjugate vaccine (PCV)
rollout.
Design: Observational cohort study.
Methods: We recruited HIV-infected adults newly attending a rural HIV clinic in
northern Malawi between 2008 and 2010. Nasopharyngeal samples were taken at
baseline and after 6, 12, 18 and 24 months. We compared pneumococcal carriage by
ART status using generalized estimated equation models adjusted for CD4þ cell count,
sex, seasonality, and other potential confounders.
Results: In total, 336 individuals were included, of which 223 individuals started ART
during follow-up. Individuals receiving ART had higher pneumococcal carriage than
individuals not receiving ART (25.9 vs. 19.8%, P¼0.03) particularly for serotypes not
included in PCV13 (16.1 vs. 9.6% P¼0.003). Following adjustment, increased carriage
of non-PCV13 serotypes was still observed for individuals on ART, but results for all
serotypes were nonsignificant [all serotypes: adjusted risk ratio (aRR) 1.22 (0.95–1.56);
non-PCV13 serotypes: aRR 1.72, 95% CI 1.13–2.62].
Conclusion: Pneumococcal carriage in HIV-infected adults in Malawi remained high
despite use of ART, consistent with failure of mucosal immune reconstitution in the
upper respiratory tract. There was evidence of increased carriage of non-PCV13
serotypes. HIV-infected adults on ART could remain an important reservoir for pneu-
mococcal diversity post infant pneumococcal vaccine introduction. Control of pneu-
mococcal disease in African HIV remains a priority.
Copyright  2015 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Streptococcus pneumoniae is a leading cause of morbidity and
mortality worldwide. As a leading cause of bacterial
pneumonia, meningitis and sepsis, the pneumococcus is
estimated to cause 11% of all-cause mortality in children
1–59 months worldwide [1]. HIV-infected adults and
children are at 20-fold to 100-fold higher risk of invasive
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pneumococcal disease (IPD) [2–4]. In sub-Saharan
Africa, IPD in adults is strongly associated with HIV
infection and has a high mortality rate [5–8].
Nasopharyngeal carriage of pneumococci is believed to be
a prerequisite for IPD, although the underlying mechan-
isms remain to be established. Pneumococcal carriage is
more common in HIV-infected than HIV-uninfected
individuals [9–11]. The nasopharynx also acts as the main
reservoir for pneumococcal transmission [12]. Exclusion of
pneumococci from this site prevents transmission and is the
mechanism underlying the herd protection generated by
pneumococcal conjugate vaccines (PCVs).
Antiretroviral therapy (ART) reduces the incidence of
IPD in HIV-infected adults [2] and there is a strong
temporal relationship between large-scale ART intro-
duction and declines in IPD in Malawi [13,14]. This
population impact will be driven by immune reconstitu-
tion and/or immune maintenance at the individual level.
However, HIV-infected individuals established on ART
remain at much higher risk of IPD as compared with
HIV-uninfected individuals [15]. This suggests immune
reconstitution is incomplete; a finding supported by
earlier work in Malawi suggesting that ART did not alter
the risk of recurrent IPD events [16].
There is limited information on the effect of ART on
pneumococcal carriage in HIV-infected adults. Three
studies have reported carriage prevalence in ART-treated
adults with diverging results. In two immunological
studies on HIV-infected Malawian adults, carriage was
highest in those receiving ART for more than 12 months
[9,17]. The third study in HIV-infected Brazilian adults
reported a lower risk of colonization in ART-treated
individuals [18]. The major limitation in these three
studies was the lack of control for potential confounders
such as child contacts, whereas the studies in Malawi were
not powered to investigate carriage epidemiology
effectively. Based on the drop in IPD since introduction
of ART in Malawi and the impact of immune
reconstitution, we hypothesized that pneumococcal
carriage in individuals would decrease when established
on ART. Using a cohort design and recruiting attendees
at a rural HIV clinic in northern Malawi, we investigated
the impact of ART on pneumococcal carriage in
Malawian adults infected with HIV. The study was
undertaken prior to introduction of 13-valent pneumo-
coccal conjugate vaccine (PCV13) in the infant
immunization schedule in October 2011.
Methods
Study design
This study is part of a cohort study on ART eligibility,
adherence and outcomes, as described elsewhere [19]. The
study was set in a rural HIV clinic within the area covered
by the Karonga Health and Demographic Surveillance
System (HDSS) in northern Malawi [20]. HIV prevalence
in the area was estimated at 7.1% in men and 9.2% in
women in 2008/2009 [21]. ARTwas available in the study
clinic since 2006. At the time of the study, individuals were
eligible for ART if they had clinical features consistent with
WHO disease stage 3 or 4, or had a CD4þ cell count of
less than 250 cells/ml, as per government guidelines. All
individuals attending ART clinic were offered cotrimox-
azole prophylactic treatment. Pneumococcal vaccination
was not provided to HIV-infected adults at the time of the
study. All HIV-infected adults and adolescents (>15 years)
living in theHDSSwhonewlyattended the clinic and were
not already taking ARTwere invited to participate in the
cohort study from January 2008. Detailed clinical datawere
obtained at baseline and on follow-up visits every 3
months. CD4þ cell counts were recorded at baseline and at
6 monthly intervals. Viral loads were recorded at baseline
and at 6 months after treatment initiation. Individuals not
qualifying for ARTat baseline were assessed on subsequent
visits for qualification. Treatment failure was assessed as a
CD4þ cell count less than 100 cells/ml or a fall of CD4þ
cell count below pretherapy baseline after at least 12
months on ART and/or a viral load more than
10 000 copies/ml after at least 6 months on ART despite
good adherence. Poor adherence was defined as missing
more than 3 days of therapy in 3 months.
This study on the effect of ART on pneumococcal
carriage included all individuals recruited between
February 2008 and May 2010. Nasopharyngeal samples
were taken at baseline and at 6-monthly intervals from
individuals returning to the HIV clinic until February
2011. We included all individuals with a baseline and at
least one follow-up result in the analysis.
The cohort was established with the primary objective of
understanding outcomes of HIV care delivery in adults
resident in the HDSS. We expected to recruit 500
participants of whom 300 would be commenced on
ART. Under these circumstances, we would have 80%
power to detect a fall in nasopharyngeal carriage by 40%
or more following ART initiation from a baseline
prevalence of 25% (two-tailed alpha 0.05).
Laboratory procedures
Nasopharyngeal samples were collected and analyzed
according to standard procedures [22]. A calcium alginate
swab (Medical Wire & Equipment, Corsham, UK) was
inserted into the posterior nasopharynx and transported
in skim milk-tryptone-glucose-glycerol medium. Inocu-
lated vials were stored at 20oC within 6 h of collection,
and frozen at 80oC until tested. Samples were cultured
on gentamicin blood agar and incubated overnight at
37oC with 5% CO2. Pneumococci were identified by
morphology and sensitivity for optochin. One colony was
isolated and cultured in Todd–Hewitt broth. Pneumo-
cocci were serogrouped using latex agglutination and
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serotyped by the Quellung reaction using standard
antisera (Statens Serum Institut, Copenhagen, Denmark).
Reagents were available to type 48 of the potential
92 serotypes, including the PCV13 serotypes (1, 3, 4, 5,
6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F).
Data analysis
We compared pneumococcal carriage prevalence
between individuals started on ART and individuals
not started on ART. Individuals starting ART during the
follow-up period contributed observation time to both
non-ART and ART groups. Proportions of pneumo-
coccal carriage were tested using the chi-square or Fisher’s
exact test as appropriate.
Crude and adjusted risk ratios (RR and aRR) for
pneumococcal carriage by ART status were obtained by
log-binomial regression using generalized estimated
equations models with an exchangeable correlation
structure and robust standard errors to account for any
within-person clustering of the data [23]. Other factors
considered were sex, age, CD4þ cell count, cotrimox-
azole use, WHO-defined clinical disease stage and
household composition. For seasonality, parametric
functions with different numbers of sin-cosine waves
were examined. For instance, a model with two sin-
cosine waves was specified as:
yi;t ¼ aþ b1sin
2pt
365
 
þ b2cos
2pt
365
 
þb3sin
4pt
365
 
þ b4cos
4pt
365
 
þb5ARTi;t þ b6 covariatesi;t
where yi,t is the carriage in individual i on day of the year t,
b1–4 terms are regression coefficients for each sine and
cosine function, ART is a binomial variable of the
individual’s ART-status and covariates are other factors
studied.
Sensitivity analyses
Missing CD4þ cell count data were estimated for
individuals with at least two CD4þ cell counts available
by simple linear regression on two CD4þ cell counts
closest in time to the missing data point. Sensitivity
analysis was performed excluding individuals with poor
adherence or treatment failure. A separate sensitivity
analysis was performed including only those individuals
that started ART at some point during follow-up.
Ethics
Informed written consent was obtained from all
participants. Ethical approval was granted by the National
Health Sciences Research Committee in Malawi and the
London School of Hygiene and Tropical Medicine
ethics committee.
Results
In total, 468 individuals newly attended the ART clinic
between February 2008 and May 2010. Seventy-two
individuals (15.4%) did not revisit the ART clinic because
they died (n¼ 22) or departed from the study area
(n¼ 23) within 6 months of recruitment or were lost to
follow-up for unknown reasons (n¼ 27). At least one
follow-up visit was recorded for 396 individuals (84.6%).
At least two nasopharyngeal specimens (one at baseline,
one at follow-up) were taken from 363 individuals
(91.6%). For 26 individuals (7.2%) sample results were not
available. One individual was excluded from the analysis
because of unknown ART start date.
In total, 336 individuals were included in the analysis, of
which 233 individuals started ART during follow-up
(Table 1). Individuals completed on average 15.7 months
of ART during the follow-up period (range 5–31
months). On average, three nasopharyngeal samples were
available per person. The average number of samples was
slightly higher in individuals who started ART during
follow-up as compared with those who did not (3.1 vs.
2.9 samples, P¼ 0.06). More women (n¼ 207) than men
(n¼ 129) attended the ART clinic and participated in the
study (P< 0.001). Poor adherence was observed for five
individuals (2.2%). Treatment failure was observed for 23
of 209 (11.0%) individuals with good adherence and
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Table 1. Baseline characteristics of HIV-infected adults who started antiretroviral therapy during the follow-up period or not.
Started ART during follow-up (n¼233) Not started ART during follow-up (n¼103)
Female sex 131 (56.2%) 76 (73.8%)
Age, (mean, SD) 39.9, SD¼10.3 37.8, SD¼11.4
CD4þ cell count (median, IQR) 174 cells/ml (86–280) 462cells/ml (365–653)
WHO clinical disease stage Stage 1: 31 (13.3%) Stage 1: 34 (33.0%)
Stage 2: 77 (33.0%) Stage 2: 69 (67.0%)
Stage 3: 101 (43.3%) Stage 3: 0 (0%)
Stage 4: 24 (10.3%) Stage 4: 0 (0%)
Pneumococcal carriage 49 (21.0%) – all types 22 (21.4%) – all types
26 (11.1%) – PCV13 types 10 (9.7%) – PCV13 types
23 (9.9%) – non-PCV13 types 12 (11.7%) – non-PCV13 types
ART, antiretroviral therapy; IQR, interquartile range; PCV, pneumococcal conjugate vaccine; SD, standard deviation.
repeated CD4þ cell count and/or viral load results
available. Cotrimoxazole prophylactic treatment was
reported to be taken during part or all of the follow-
up period by 94.8% (221/233) of individuals receiving
ART during follow-up and 81.5% (84/103) of individuals
who did not receive ART during follow-up.
Pneumococcal carriage was detected in 232 out of 1027
samples (22.6%). Pneumococcal carriage prevalence at
baseline was similar in individuals who subsequently
received ART compared with those who did not (21.0 vs.
21.4%, P¼ 0.99). Median CD4þ cell count increased
over time in patients started on ART, but no decrease in
pneumococcal carriage was observed (Fig. 1). Individuals
started on ART were more likely to have pneumococcal
carriage than individuals not started on ART at all
subsequent sampling points (25.6 vs. 17.9%, P¼ 0.03)
(Fig. 1). Among individuals on ART, carriage did not
differ between those who had undetectable or low
(400 copies/ml) viral loads and those who had viral
loads more than 400 copies/ml at 6 months after
treatment initiation (26.1 vs. 23.3%, P¼ 0.84). In the
multivariable analysis including all samples, increased
carriage was still observed for individuals on ART, but
results were nonsignificant (aRR 1.22, 95% CI 0.95–
1.56) (Table 2). Similar results were maintained when
omitting results from individuals with treatment failure or
poor adherence (aRR 1.25, 95% CI 0.96–1.63). In
the sensitivity analysis with imputed CD4þ cell count
data a significant increase in carriage was observed for
ART-treated individuals (aRR 1.29, 95% CI 1.03–1.62).
Including only individuals who received ART during
the follow-up period (n¼ 233) resulted in a weaker
association in the same direction (aRR 1.17, 0.86–1.60).
There was no evidence that among individuals on ART
pneumococcal carriage differed by duration of treatment
(Table 2, Fig. 1).
Most common serotypes isolated were 3 (9.1% of
isolates), 19F (6.5%), 6B (5.2%), 11 (4.7%) and 23F
(4.7%) (Fig. 2). Sixty-six isolates (28.4%) could not be
fully typed with the available reagents. There was weak
evidence that the diversity of serotypes carried was greater
in the ART-treated group than in the ART-untreated
groups (32 serotypes in 87 typable isolates vs. 25 serotypes
in 79 typable isolates): a comparison of bootstrapped
Shannon diversity indices gave a simulated P value of
0.08. In a pooled analysis of all time points, carriage of
PCV13 serotypes did not differ between individuals on
ART or not (9.9 vs. 10.2%, P¼ 0.94), but carriage of
non-PCV13 serotypes was higher in individuals on ART
(16.1 vs. 9.6% P¼ 0.003). Carriage of non-PCV13
serotypes remained significantly higher in the ART-
treated group after adjustment in the multivariable
analysis (aRR 1.72, 95% CI 1.13–2.62) (Table 2).
Low CD4þ cell count was associated with higher
pneumococcal carriage prevalence (aRR 1.40, 95% CI
1.08–1.82 for 250 vs. >250 cells/ml). There was no
evidence for an association between pneumococcal
carriage and cotrimoxazole prophylactic treatment
(aRR 0.95, 95% CI 0.68–1.34). Female sex was
associated with higher pneumococcal carriage prevalence
(aRR 1.74, 95% CI 1.26–2.40). Individuals living in
large households seemed to be more likely to carry a
pneumococcus than individuals living in small house-
holds (aRR 1.52, 95% CI 0.95–2.41 for 0–2 vs. 8–15
household members). There was no evidence for an
association between pneumococcal carriage and living
with children younger than 5 years of age (aRR 1.05,
95% CI 0.81–1.37). Pneumococcal carriage showed
strong seasonality with a model with two sine-cosine pairs
providing the best fit (Fig. 3). Carriage prevalence was
higher in the cold (May-August) and hot (September-
November) seasons as compared to the rainy season
(December-April).
Discussion
This cohort study provides strong evidence that
pneumococcal carriage in HIV-infected adults remains
high during the first two years of ART use, with a
tendency to increased carriage of non-PCV13 serotypes.
Two immunological studies from Malawi have reported
consistent findings [9,17], but this is the first cohort study
that addresses important confounders for pneumococcal
carriage and provides robust measures of association.
Several of our risk factors for carriage are well known. We
found that females are at higher risk of pneumococcal
carriage, consistent with their higher contact rates with
1840 AIDS 2015, Vol 29 No 14
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Fig. 1. Pneumococcal colonization and median CD4R cell
count on baseline and by month since ART/month since
baseline in patients receiving ART or not. ART, antiretroviral
therapy.
young children in which pneumococcal carriage is
greatest. However, household contact with children less
than 5 years was not found to be independently associated
with pneumococcal carriage in HIV-infected adults. A
possible explanation for this inconsistency is that child
contact may be universal amongst women and not
determined by household contact only. Strong seasonality
patterns were observed in this study, with lowest carriage
observed in the rainy season. This finding is consistent
with another household cohort study on pneumococcal
carriage conducted in the same study area in 2009–2011
[24].
Our findings are consistent with two immunological
studies of HIV-infected adults in Malawi which reported
continued high pneumococcal carriage over a period of
12–18 months on ART [9,17]. Both studies reported
failure of mucosal immune responses to normalize after
initiation of ART. Similar incomplete mucosal CD4þ
T-cell immune reconstitution has frequently been
Effect of antiretroviral therapy on pneumococcal carriage Heinsbroek et al. 1841
Table 2. Risk ratios and 95% confidence intervals of risk factors associated with pneumococcal carriage in HIV-infected adults.
Risk factor n
Carriage
Crude RR 95% CI P aRR 95% CI Pn %
ART
Carriage of all serotypes
Not on ART 560 111 19.8 – –
On ART 467 121 25.9 1.29 1.02–1.62 0.03 1.22 0.95–1.56 0.12
Carriage of PCV13 serotypes
Not on ART 560 57 10.2 – –
On ART 467 46 9.9 0.96 0.68–1.37 0.84 0.87 0.57–1.33 0.51
Carriage of non-PCV13 serotypes
Not on ART 560 54 9.6 – –
On ART 467 75 16.1 1.64 1.19–2.27 0.003 1.72 1.13–2.62 0.01
Months on ART
0 (at start ART) 233 53 22.7 – –
6 153 41 26.8 1.20 0.76–1.91 0.43 1.26 0.88–1.80 0.21
12 143 33 23.1 1.06 0.68–1.64 0.80 0.85 0.54–1.33 0.47
18 87 19 21.8 0.99 0.57–1.72 0.98 1.03 0.63–1.66 0.92
24 68 23 33.8 1.92 1.10–3.34 0.02 1.59 1.09–2.33 0.02
Sex
Men 392 61 15.6 – –
Women 635 171 26.9 1.68 1.25–2.27 <0.001 1.74 1.26–2.40 <0.001
Age (years)
<31 153 45 29.4 – –
31–40 424 99 23.3 0.80 0.58–1.10 0.18 0.84 0.60–1.17 0.30
41–50 262 56 21.4 0.76 0.53–1.08 0.13 0.85 0.60–1.21 0.38
>50 188 32 17.0 0.58 0.38–0.89 0.01 0.78 0.48–1.28 0.33
CPT
Not on CPT 418 84 20.1 – –
On CPT 609 148 24.3 1.22 0.96–1.56 0.11 0.95 0.68–1.34 0.77
CD4þ cell count (cells/ml)a
>250 549 105 19.1 – –
250 320 84 26.3 1.35 1.03–1.77 0.03 1.40 1.08–1.82 0.01
WHO stage
1 563 130 23.1 – –
2 324 71 21.9 0.92 0.71–1.18 0.50 1.13 0.85–1.49 0.40
3 112 29 25.9 1.06 0.75–1.50 0.76 1.15 0.80–1.66 0.45
4 28 2 7.1 0.34 0.12–0.99 0.05 0.37 0.10–1.45 0.15
Children <5 years in householdb
No 480 105 21.9 – –
Yes 470 109 23.2 1.03 0.79–1.33 0.85 1.05 0.81–1.37 0.70
Number of household membersb
0–2 248 52 21.0 – –
3–7 611 132 21.6 1.07 0.78–1.47 0.69 1.07 0.77–1.49 0.68
8–15 91 30 33.0 1.50 0.93–2.41 0.10 1.52 0.95–2.41 0.08
Year
2008 179 33 18.4 – –
2009 452 95 21.0 1.13 0.81–1.56 0.47 1.03 0.72–1.48 0.87
2010 395 103 26.1 1.38 0.98–1.95 0.06 1.29 0.85–1.95 0.23
RRs were estimated from log-binomial regression models. Within-person clustering was adjusted for using the generalized estimating equations
method. ART, seasonality (parametric spline fit), CD4þ cell count and sex were included in the multivariable analysis. Analysis on all serotypes
unless specified otherwise. aRR, adjusted risk ratio; ART, antiretroviral therapy; CI, confidence interval; CPT, cotrimoxazole prophylactic
treatment; PCV, pneumococcal conjugate vaccine; RR, risk ratio.
aCD4þ cell count missing for 158 observations (15.4%). Estimation by linear regression for 137 observations from individuals with at least two
CD4þ cell counts available resulted in an aRR for the association of ART with pneumococcal carriage of all serotypes of 1.29 (95% CI 1.03–1.62).
bHousehold information missing for 77 observations (7.5%).
reported in gut-associated lymphoid tissue [25]. Our
findings differ from the two smaller Malawian studies in
that we did not find a difference in pneumococcal
carriage between symptomatic and asymptomatic HIV-
infected adults. We did find evidence for higher carriage
of non-PCV13 serotypes, providing further evidence for
the hypothesis of ‘loss of control’ of pneumococcal
carriage among ART-treated adults that was generated
from the immunological studies [9,17]. A cross-sectional
study from Brazil reported stable ART for 1 year or more
was associated with lower odds of pneumococcal carriage
[18]. This study was highly male biased (70% in Brazil vs.
38% in our study) and reported low household contact
with young children (18% in Brazil vs. 50% in our study),
representing different demography and risk factors from
African HIV-infected populations.
A decrease in IPD has been observed since rollout of ART
in Malawi [13], yet no decrease in pneumococcal carriage
was observed in individuals established on ART. There are
several possible explanations for this finding. At an
individual level ART-mediated immune reconstitution
may have a different impact on antipneumococcal mucosal
responses than on systemic responses necessary for the
control of IPD. Incomplete recovery of both mucosal and
systemic response to the pneumococcus have been
measured [9,17,26] and a mechanism for differential
recovery mediated by Tregulatory cells has been suggested
from murine studies [27,28]. Behavioural changes as a
result of improved well-being on ART may result in
increased social mixing and thus more exposure to
pneumococcal transmission. Extending this further,
reduced use of antibiotics as a consequence of improved
health may lead to less clearance of pneumococcal carriage.
The latter explanation is unlikely given the lack of impact
of cotrimoxazole on carriage observed in this study.
Several limitations can be identified for this study. Our
two-tailed sample size calculations were limited by the
geographical boundaries of the cohort and based on a
hypothesized 40% change in pneumococcal carriage in
ART-treated adults. We recruited less participants than
anticipated: 336 were included in this study of which 233
started ART instead of an expected number of 500
participants of whom 300 would commence on ART.
Despite this lower sample size than anticipated we can
confidently refute our initial hypothesis and conclude that
pneumococcal carriage does not decrease after ART
initiation. Our study only included data from the first
2 years of ART initiation. It is possible that different
results would be found for a prolonged time on ART.
Despite adjusting for CD4þ cell count, WHO-defined
disease stage and other potential confounders, residual
confounding must also be considered with individuals
receiving ART differing from individuals not receiving
ART during the study period. A self-controlled analysis
including only the 233 individuals receiving ART during
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vaccine.
follow-up found similar results as reported for the full
cohort, suggesting major confounders were not missed.
Our laboratory procedures did not allow for detection of
simultaneous colonization with multiple serotypes. This
will not have impacted our comparison of pneumococcal
carriage by ART status but may have affected our
conclusions over serotype diversity. Six-month sampling
intervals are too long to study carriage duration and
investigate whether our findings can be explained by
similar carriage incidence but a prolonged carriage in
HIV-infected adults on ART. We used a self-reported
definition for poor adherence. Underreporting of poor
adherence as a result of social desirability could have led to
misclassification of patients. The impact of misclassifi-
cation will have been minimized, however, as patients
with unreported poor adherence are likely to have been
classified under treatment failure, for which the definition
relied on CD4þ cell count and viral load measurements
only. In the sensitivity analysis, similar results were
maintained when omitting results from individuals with
treatment failure or poor adherence.
These findings have implications for HIV care and
potentially broader public health. The results indicate a
continued respiratory mucosal immune defect after up to
2 years of ART and are consistent with the continued
increased risk of IPD in this population. How long and
why this defect persists merits further investigation
through follow-up studies. In the meantime it is clear that
prophylactic measures to prevent pneumococcal disease
remain a priority and a better understanding of the
burden of noninvasive pneumococcal disease is required.
Rates of IPD have fallen, but pneumonia remains a
common and serious problem in the HIV clinic and
requires a renewed focus of attention.
Pneumococcal conjugate vaccination is known to work in
this population. It has not been recommended for use on
the expectation of HIV-infected adults benefiting from
herd protection following the introduction of infant
pneumococcal vaccination into the Malawi expanded
programme on immunization schedule. However, the
observed high rates of carriage in HIV-infected adults may
have implications for pneumococcal transmission and
consequently for the scale of herd protection. It is unclear
how important HIV-infected adults are in pneumococcal
transmission, but they represent a large reservoir of S.
pneumoniaewhich is not reduced by ART in at least the first
2 years of treatment. Herd protection following infant
PCV has to date been demonstrated in developed regions
with low prevalence pneumococcal carriage in adults [29]
and in African centres with low HIV prevalence [30–32].
In South Africa, declines in vaccine-type carriage [33] and
IPD [34] in unvaccinated adults suggest indirect effects of
PCV in the context of high HIV-burden, although it is
difficult to distinguish vaccine effects from an ongoing
background drop in pneumococcal carriage that predates
the introduction of PCV. Surveillance of pneumococcal
carriage as well as disease in HIV-infected adults during
PCV rollout would be a prudent measure in Malawi and
countries with similar generalized HIV epidemics.
Vaccination of HIV-infected adults could be considered
to provide both direct protection and maximize herd
protection.
In summary, pneumococcal carriage in HIV-infected
adults in Malawi remained high despite 2 years of ART,
with evidence of increased carriage of non-PCV13
serotypes. Following PCV introduction monitoring of
carriage in HIV-infected adults should be undertaken to
determine whether they continue to be at risk of vaccine
serotype pneumococcal disease and whether they
constitute a reservoir for persisting vaccine serotype
carriage and pneumococcal diversity.
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